var data={"title":"Juvenile xanthogranuloma (JXG)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Juvenile xanthogranuloma (JXG)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/contributors\" class=\"contributor contributor_credentials\">Kate B P&uuml;ttgen, MD, FAAD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 07, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H12028554\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Juvenile xanthogranuloma (JXG) is a benign, proliferative disorder of histiocytic cells of the dermal dendrocyte phenotype. JXG belongs to the broad group of non-Langerhans cell histiocytoses and is typically a disorder of early childhood. JXG typically presents in the first two years of life as a solitary, reddish or yellowish skin papule or nodule (<a href=\"image.htm?imageKey=DERM%2F69122\" class=\"graphic graphic_picture graphicRef69122 \">picture 1D</a>), most often on the head, neck, or upper trunk. Histologically, JXG is characterized by the presence of histiocytes, foam cells, and Touton giant cells. JXG generally follows a benign course with spontaneous resolution over a period of a few years. Less commonly skin lesions can be multiple (<a href=\"image.htm?imageKey=DERM%2F81058\" class=\"graphic graphic_picture graphicRef81058 \">picture 2B</a>). Extracutaneous or systemic forms are exceedingly rare and can be associated with considerable morbidity. </p><p>An overview of JXG will be presented here. Langerhans cell histiocytosis is discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;</a> and <a href=\"topic.htm?path=langerhans-cell-histiocytosis-eosinophilic-granuloma-of-bone-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children and adolescents&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H12028561\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JXG is the most common of the non-Langerhans cell histiocytoses [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/1\" class=\"abstract_t\">1</a>]. The incidence is unknown. In a large tumor registry spanning 35 years, JXG accounted for 129 of 24,600 pediatric tumors (0.5 percent) [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2\" class=\"abstract_t\">2</a>]. However, this figure may be an underestimate of the relative frequency of JXG since many cases are diagnosed on clinical grounds without histologic confirmation. In a survey of 122 dermatologists with an average of 12 years of practice, 2371 cases of JXG were reported (an average of less than two cases per dermatologist per year); only 7 cases had ocular involvement [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/3\" class=\"abstract_t\">3</a>].</p><p>JXG may be present at birth [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/4\" class=\"abstract_t\">4</a>]. Between 40 and 70 percent of JXG arise in the first year of life [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/5\" class=\"abstract_t\">5</a>]. The median ages of onset in two large case series were 5 months (range 0 to 244 months) and 1 year (range 0 to 20 years) [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2,6\" class=\"abstract_t\">2,6</a>]. The male to female ratio was about 1.4:1.</p><p>The prognosis of JXG is generally good, with spontaneous resolution of skin and organ lesions over a few years. Rare fatalities have been reported in infants with central nervous system or massive hepatic involvement [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2,6-9\" class=\"abstract_t\">2,6-9</a>]. (See <a href=\"#H12028617\" class=\"local\">'Prognosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H12028568\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cause of JXG is unknown. It is a member of the group of histiocytoses, disorders of the mononuclear phagocytic system, which have a broad range of clinical presentations and prognoses.</p><p>All histiocytoses arise from CD34<sup>+</sup> stem cells, which develop, based on the cytokine milieu, into CD14<sup>+</sup> or CD14<sup>-</sup> cells. Langerhans cells (LC) and Langerhans cell histiocytoses (LCH) derive from CD14<sup>-</sup> cells. CD14<sup>+</sup> cells may become <span class=\"nowrap\">monocyte/macrophage</span> lineage or <span class=\"nowrap\">dermal/interstitial</span> dendrocytes, the latter considered to be the precursor cell of non-LCH [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/1,10\" class=\"abstract_t\">1,10</a>]. </p><p class=\"headingAnchor\" id=\"H432992506\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Classic histology of JXG shows a mixed dermal infiltrate of mononuclear cells, multinucleated giant cells with or without the features of Touton giant cells (characterized by a ring or wreath of nuclei surrounded by a foamy cytoplasm), and spindle cells. Lymphocytes, eosinophils, neutrophils, and mast cells can be seen. The lesion is non-encapsulated but well demarcated, with dense sheets of cells infiltrating the dermis and the upper portion of the subcutaneous fat. Epidermis and adnexae are spared, though the epidermis can be thinned and rarely ulcerated. </p><p>The microscopic appearance depends upon the age of the lesion. Early JXG shows only histiocytes, or spindle-shaped fibrohistiocytic cells, minimally lipidized. More mature JXG show foamy, lipid-laden vacuolated mononuclear cells and Touton giant cells. Regressing lesions show progressive replacement by fibrous tissue [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>Immunostaining is important in establishing the diagnosis. JXG stains positively for Factor XIIIa, a marker of interstitial dendrocytes, CD68, CD163, CD14, and fascin. Stains for S100 and CD1a, the latter of which is specific for Langerhans cells, are negative.</p><p class=\"headingAnchor\" id=\"H12028575\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H5404120\"><span class=\"h2\">Clinical presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JXG typically presents as a reddish or yellowish to brown papule, plaque, or nodule (<a href=\"image.htm?imageKey=DERM%2F69122\" class=\"graphic graphic_picture graphicRef69122 \">picture 1D</a>). A size of 0.5 to 2 cm is typical. The lesions can occur in any location, and are most common on the head, neck, and upper trunk. Early lesions tend to be more red and raised, but as they mature and become progressively more lipidized, they appear more yellow and will often flatten. Fine telangiectasias occasionally can be seen overlying the lesion. The lesions usually are solitary (<a href=\"image.htm?imageKey=DERM%2F68132%7EDERM%2F81386%7EDERM%2F59377%7EDERM%2F69122\" class=\"graphic graphic_picture graphicRef68132 graphicRef81386 graphicRef59377 graphicRef69122 \">picture 1A-D</a>), but multiple lesions (<a href=\"image.htm?imageKey=DERM%2F68597%7EDERM%2F81058\" class=\"graphic graphic_picture graphicRef68597 graphicRef81058 \">picture 2A-B</a>), and extracutaneous and systemic involvement may occur. All organs and systems can be affected. </p><p>The most common extracutaneous presentation is a solitary nodule or mass in the subcutaneous or deep soft tissues [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/6\" class=\"abstract_t\">6</a>]. Systemic lesions may occur in the liver, lung, spleen, lymph nodes, bones, and the gastrointestinal tract [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Eye involvement is rare (0.3 percent of cases identified by dermatologists in one report [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/3\" class=\"abstract_t\">3</a>]). It occurs in young children, often without skin involvement. (See <a href=\"#H12028582\" class=\"local\">'Ocular JXG'</a> below.) </p><p>In two large case series, the distribution of clinical manifestations was as follows [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2,6\" class=\"abstract_t\">2,6</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Solitary skin lesion &ndash; 67 and 71 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple skin lesions &ndash; 7 and 10 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superficial or deep soft tissue lesions &ndash; 16 percent and 15 percent </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic involvement (with or without skin lesions) &ndash; 4 percent and 5 percent</p><p/><p>The most severe cases tend to occur in very young children. In a series of 36 systemic cases the median age was 0.3 years (range 0 to 12 years) [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/7\" class=\"abstract_t\">7</a>]. In a study of 45 cases of fetal and neonatal JXG, systemic involvement was observed in 12 patients, 9 of whom had multiple skin lesions [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/4\" class=\"abstract_t\">4</a>]. Liver, lung, spleen, lymph nodes, skeleton, and the gastrointestinal tract were the most common sites involved. </p><p class=\"headingAnchor\" id=\"H5404113\"><span class=\"h2\">Clinical course</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Spontaneous regression is the rule for skin lesions, and occurs in approximately one to five years [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/4\" class=\"abstract_t\">4</a>], sometimes leaving an atrophic or hyperpigmented scar. Extracutaneous and systemic JXG also spontaneously regress in most cases. </p><p>Cases in newborns with multisystem or extensive visceral involvement may require aggressive treatment, but fatalities are exceedingly rare [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2,6\" class=\"abstract_t\">2,6</a>]. (See <a href=\"#H12028610\" class=\"local\">'Management'</a> below.)</p><p class=\"headingAnchor\" id=\"H12028582\"><span class=\"h2\">Ocular JXG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ocular JXG typically occurs in young children. The iris (<a href=\"image.htm?imageKey=DERM%2F56332\" class=\"graphic graphic_picture graphicRef56332 \">picture 3B</a>) is the most frequent site of ocular involvement, but the lid (<a href=\"image.htm?imageKey=DERM%2F75895\" class=\"graphic graphic_picture graphicRef75895 \">picture 3A</a>), orbit, ciliary body, cornea, and episclera may also be affected. Red eye and hyphema (bleeding into the anterior chamber of the eye) are the most common presenting complaints in patients with ocular JXG. Uveitis, heterochromia iridis, or iris masses (<a href=\"image.htm?imageKey=DERM%2F56332\" class=\"graphic graphic_picture graphicRef56332 \">picture 3B</a>) can also occur [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/11\" class=\"abstract_t\">11</a>]. </p><p>Secondary unilateral glaucoma can occur as a result of acute rise in intraocular pressure from mass effect of blood or the JXG itself, and can cause blindness. (See <a href=\"topic.htm?path=overview-of-glaucoma-in-infants-and-children#H9\" class=\"medical medical_review\">&quot;Overview of glaucoma in infants and children&quot;, section on 'Secondary glaucoma'</a>.) Posterior segment involvement is rare [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Cutaneous JXGs are absent in approximately one-half of cases of ocular JXG at the time of presentation but may develop before, simultaneous with, or after ocular lesions [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/5\" class=\"abstract_t\">5</a>]. </p><p class=\"headingAnchor\" id=\"H432992837\"><span class=\"h1\">ASSOCIATED CONDITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Juvenile xanthogranuloma (JXG) has been reported in approximately 5 to 10 percent of patients with neurofibromatosis type 1 (NF1) and in approximately 30 percent of NF1 patients younger than 2 years [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/14,15\" class=\"abstract_t\">14,15</a>]. In young children, the presence of multiple caf&eacute; au lait macules and JXG may be a marker of NF1 even in the absence of other reliable diagnostic signs of NF1 [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p>An association between JXG, neurofibromatosis type 1, and juvenile myelomonocytic leukemia (a rare form of childhood leukemia) has been described in a few single case reports [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/16-22\" class=\"abstract_t\">16-22</a>]. However, the clinical implications of this triple association are unclear [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/14,23\" class=\"abstract_t\">14,23</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia#H11\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic myeloid leukemia&quot;, section on 'Juvenile myelomonocytic leukemia'</a>.)</p><p class=\"headingAnchor\" id=\"H12028603\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnosis of JXG is made in most cases clinically, based upon clinical appearance; biopsy is infrequently performed because the clinical picture is usually so typical and because of the self-healing nature of the disease. When the diagnosis is in doubt, skin biopsy for histology and immunostaining, is necessary. (See <a href=\"#H432992506\" class=\"local\">'Pathology'</a> above.) </p><p>Dermoscopy has been suggested as a potentially useful tool for the diagnosis of JXG. The most characteristic dermoscopic finding in early to full-developed JXG is the so-called &ldquo;setting sun&rdquo; sign, which consists of a yellow-orange central area surrounded by a peripheral pink border with fine, branched linear telangiectasias; in older lesions that contain more lipidized cells, dermoscopy shows white and yellow globules [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/24\" class=\"abstract_t\">24</a>]. </p><p class=\"headingAnchor\" id=\"H5404435\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical differential diagnosis of JXG in children includes Langerhans cell histiocytosis, other xanthomatous lesions, mastocytoma, Spitz nevus, and dermatofibroma. In most cases the histologic features and immunohistochemistry staining are diagnostic (<a href=\"image.htm?imageKey=DERM%2F59870\" class=\"graphic graphic_table graphicRef59870 \">table 1</a>). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Langerhans cell histiocytosis</strong> &ndash; LCH typically presents in infancy as a refractory infantile seborrheic dermatitis with petechiae, diaper dermatitis with ulceration and erosion, cutaneous papules, and nodules (<a href=\"image.htm?imageKey=DERM%2F69504\" class=\"graphic graphic_picture graphicRef69504 \">picture 4</a>). Diabetes insipidus, hepatosplenomegaly, lymphadenopathy, and bone marrow involvement can occur. Individual lesions are typically smaller than those of JXG. On immunostaining of biopsied tissue, LCH is S100 and CD1a positive, but JXG is S100 and CD1a negative. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis#H452648848\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;, section on 'Skin and oral mucosa'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Papular xanthoma</strong> &ndash; Papular xanthoma (<a href=\"image.htm?imageKey=DERM%2F72187\" class=\"graphic graphic_picture graphicRef72187 \">picture 5</a>) is a very uncommon disease that occurs mainly in normolipidemic adults and presents as multiple yellow or red papules or nodules on the trunk and, less frequently, on the head and extremities. Rare pediatric cases have been reported [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/25-28\" class=\"abstract_t\">25-28</a>]. The histologic and immunohistochemical differentiation from JXG is difficult. Papular xanthoma presents a dense infiltrate of foam cells, with fewer Touton cells and inflammatory cells than JXG. Immunostaining for factor XIIIa was negative in a series of 10 cases [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/25\" class=\"abstract_t\">25</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tuberous xanthoma</strong> &ndash; Tuberous xanthomas occur most often in areas of pressure such as the buttocks, knees (<a href=\"image.htm?imageKey=DERM%2F104995\" class=\"graphic graphic_picture graphicRef104995 \">picture 6</a>), and elbows (<a href=\"image.htm?imageKey=DERM%2F72875%7EDERM%2F104996\" class=\"graphic graphic_picture graphicRef72875 graphicRef104996 \">picture 7A-B</a>); they are firm, asymptomatic, reddish yellow nodules, seen in patients with hypercholesterolemia and high LDL. Histologically, tuberous xanthoma consists of dermal aggregates of foam cell, with absence of Touton cells or other inflammatory cells. (See <a href=\"topic.htm?path=cutaneous-xanthomas#H714674409\" class=\"medical medical_review\">&quot;Cutaneous xanthomas&quot;, section on 'Tuberous xanthomas'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Spitz nevus</strong> &ndash; Spitz nevi presents as a single, dome shaped, pink to red papule on the face or extremities of children. Histologically, classic Spitz nevi show a symmetrical proliferation of spindle and epithelioid cells, often in nests. Immunostaining confirms the melanocytic origin (S100, Melan-a [Mart-1], and tyrosinase positive) [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=spitzoid-melanocytic-neoplasms-spitz-nevus-and-atypical-spitz-tumors\" class=\"medical medical_review\">&quot;Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mastocytoma</strong> &ndash; Mastocytomas are benign collections of mast cells within the dermis that demonstrate urtication with stroking (Darier sign). They are relatively common in children and appear as reddish to golden brown papules or plaques, which can sometimes have a rubbery feel (<a href=\"image.htm?imageKey=DERM%2F80221%7EDERM%2F50284\" class=\"graphic graphic_picture graphicRef80221 graphicRef50284 \">picture 8A-B</a>). They are generally asymptomatic but can be mildly pruritic with urtication. Pathology shows mast cells in the papillary dermis highlighted by Giemsa stain. (See <a href=\"topic.htm?path=mastocytosis-cutaneous-and-systemic-epidemiology-pathogenesis-and-clinical-manifestations#H16\" class=\"medical medical_review\">&quot;Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations&quot;, section on 'Mastocytomas of the skin'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dermatofibroma</strong> &ndash; Dermatofibromas are benign, generally asymptomatic tan to reddish brown papules, seen frequently on the extremities. They often arise after minor inflammation or trauma (eg, folliculitis or insect bite). They are seen more commonly in older children and adults than in infants. Histologically, an acanthotic epidermis with an underlying zone of normal papillary dermis is seen. The lesion is unencapsulated and collagen trapping (spindle cells encasing normal collagen) occurs at the periphery. Spindle cells overlap in fascicles and whorls. (See <a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin#H1101419831\" class=\"medical medical_review\">&quot;Overview of benign lesions of the skin&quot;, section on 'Dermatofibroma'</a>.) </p><p/><p>The differential diagnosis of JXG in older children and adults includes xanthoma disseminatum and eruptive xanthoma. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Xanthoma disseminatum</strong> &ndash; Xanthoma disseminatum is a rare, nonfamilial form of non-Langerhans cell histiocytosis occurring in young adults, with frequent involvement of mucocutaneous sites [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/30,31\" class=\"abstract_t\">30,31</a>]. It is often associated with diabetes insipidus. Numerous erythematous, yellow-brown papules and nodules are symmetrically distributed on the trunk, face, and upper extremities. Lesions may become confluent in flexural areas [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/32\" class=\"abstract_t\">32</a>].The histologic and immunohistochemical characteristics are the same as JXG.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eruptive xanthomas</strong> &ndash; Eruptive xanthomas occur in adults in the setting of hypertriglyceridemia, as crops of tiny yellowish red papules on a background of erythema (<a href=\"image.htm?imageKey=DERM%2F62471\" class=\"graphic graphic_picture graphicRef62471 \">picture 9</a>). Sites of predilection include the buttocks, shoulders, and extensor extremities. Facial and oral involvement can occur. Histologically, eruptive xanthoma consists of a dermal infiltrate of histiocytes, lymphocytes, neutrophils, and, in mature lesions, small foam cells. (See <a href=\"topic.htm?path=cutaneous-xanthomas#H714674399\" class=\"medical medical_review\">&quot;Cutaneous xanthomas&quot;, section on 'Eruptive xanthomas'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12028610\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of JXG depends upon the site(s) of involvement.</p><p class=\"headingAnchor\" id=\"H21221319\"><span class=\"h2\">Cutaneous JXG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No treatment is needed for cutaneous JXG. Reassurance to patients and parents of affected children about the benign course and spontaneous regression of the disease is usually all that is necessary. Involution usually occurs one to five years after onset [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/33\" class=\"abstract_t\">33</a>].</p><p>Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/3\" class=\"abstract_t\">3</a>]. Most patients with ocular involvement present with acute ocular complaints; asymptomatic eye involvement is rare. There are no studies of the benefits of routine ophthalmologic evaluation for children with cutaneous JXG. It is reasonable to consider referral to ophthalmology for patients under age two presenting with multiple JXG, as they may have a higher risk of ocular involvement [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H21221326\"><span class=\"h2\">Subcutaneous and soft tissue JXG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Subcutaneous and soft tissue lesions also resolve spontaneously and do not require treatment. </p><p class=\"headingAnchor\" id=\"H21221333\"><span class=\"h2\">Ocular JXG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with ocular and periocular lesions should be referred to an ophthalmologist for diagnosis and management. The treatment depends upon the type of ocular involvement and complications. </p><p>Whether children with cutaneous JXG should be referred for ophthalmologic evaluation is discussed above. (See <a href=\"#H21221319\" class=\"local\">'Cutaneous JXG'</a> above.)</p><p class=\"headingAnchor\" id=\"H21221340\"><span class=\"h2\">Symptomatic systemic JXG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic lesions that are associated with symptoms (eg, mass effect) may require treatment if they do not spontaneously regress [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/7\" class=\"abstract_t\">7</a>]. Treatment decisions for patients with symptomatic systemic JXG should be made on a case-by-case basis. Referral to an oncologist may be warranted. Treatment may involve excision, radiotherapy, <span class=\"nowrap\">and/or</span> systemic chemotherapy [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/34-38\" class=\"abstract_t\">34-38</a>].</p><p>There is no standard chemotherapeutic regimen for systemic JXG. A variety of regimens have been tried with variable results (summarized in reference [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/34\" class=\"abstract_t\">34</a>]). Most of these regimens included agents that are used in the treatment of LCH (eg, <a href=\"topic.htm?path=vinblastine-pediatric-drug-information\" class=\"drug drug_pediatric\">vinblastine</a>, <a href=\"topic.htm?path=prednisone-pediatric-drug-information\" class=\"drug drug_pediatric\">prednisone</a>, <a href=\"topic.htm?path=methotrexate-pediatric-drug-information\" class=\"drug drug_pediatric\">methotrexate</a>, and <a href=\"topic.htm?path=mercaptopurine-pediatric-drug-information\" class=\"drug drug_pediatric\">mercaptopurine</a>). Central nervous system involvement has been successfully treated with <a href=\"topic.htm?path=cladribine-pediatric-drug-information\" class=\"drug drug_pediatric\">cladribine</a> (2-chlorodeoxyadenosine) [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/39,40\" class=\"abstract_t\">39,40</a>]. In one patient, extracutaneous JXG was successfully treated with <a href=\"topic.htm?path=thalidomide-pediatric-drug-information\" class=\"drug drug_pediatric\">thalidomide</a> after failure of other chemotherapeutic regimens [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H12028617\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prognosis of cutaneous JXG is uniformly good; spontaneous regression is the rule. Patients may have residual hyperpigmentation, minimal atrophy, or anetoderma (loss of elastic fibers in the dermis) following regression [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>Extracutaneous JXG most often regress spontaneously as well, although treatment may be needed to relieve symptoms due to mass effect. Long-term sequelae are rarely reported. Fatalities are extremely rare, typically in infants with central nervous system or massive hepatic involvement and liver failure [<a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2,6-9,42\" class=\"abstract_t\">2,6-9,42</a>].</p><p class=\"headingAnchor\" id=\"H12028624\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JXG is a rare benign, proliferative histiocytic disorder of dermal dendrocyte origin, and is the most common of the non-Langerhans cell histiocytoses. It occurs predominantly in young children. (See <a href=\"#H12028561\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical skin lesions appear as reddish to yellow papules, plaques, or nodules, most often on the head and neck, and upper trunk (<a href=\"image.htm?imageKey=DERM%2F69122\" class=\"graphic graphic_picture graphicRef69122 \">picture 1D</a>). Extracutaneous or systemic JXG is rare, occurring in about 4 percent of all cases, and may involve every organ or system, including the eye (<a href=\"image.htm?imageKey=DERM%2F75895%7EDERM%2F56332\" class=\"graphic graphic_picture graphicRef75895 graphicRef56332 \">picture 3A-B</a>). (See <a href=\"#H5404120\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ocular JXG may occur in the absence of skin lesions, and usually presents with ocular manifestations (hyphema, uveitis, iris or corneal lesions) (<a href=\"image.htm?imageKey=DERM%2F75895%7EDERM%2F56332\" class=\"graphic graphic_picture graphicRef75895 graphicRef56332 \">picture 3A-B</a>). (See <a href=\"#H12028582\" class=\"local\">'Ocular JXG'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis is clinical in most cases. In difficult cases, histology and immunohistochemistry are diagnostic. (See <a href=\"#H12028603\" class=\"local\">'Diagnosis'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of cutaneous JXG includes Langerhans cell histiocytosis (<a href=\"image.htm?imageKey=DERM%2F69504\" class=\"graphic graphic_picture graphicRef69504 \">picture 4</a>); other xanthomatous lesions (such as papular xanthoma, tuberous xanthoma, xanthoma disseminatum, and eruptive xanthoma); Spitz nevus; mastocytoma; and dermatofibroma. (See <a href=\"#H5404435\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous JXG generally regresses spontaneously; reassurance about the benign course is usually all that is necessary. Patients with ocular JXG should be referred to an ophthalmologist. Systemic JXG may require treatment (excision, radiotherapy, <span class=\"nowrap\">and/or</span> chemotherapy) if it causes symptoms. (See <a href=\"#H12028610\" class=\"local\">'Management'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/1\" class=\"nounderline abstract_t\">Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45:256.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/2\" class=\"nounderline abstract_t\">Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol 2005; 29:21.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/3\" class=\"nounderline abstract_t\">Chang MW, Frieden IJ, Good W. The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol 1996; 34:445.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/4\" class=\"nounderline abstract_t\">Isaacs H Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006; 47:123.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/5\" class=\"nounderline abstract_t\">Hernandez-Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol 1997; 36:355.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/6\" class=\"nounderline abstract_t\">Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003; 27:579.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/7\" class=\"nounderline abstract_t\">Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996; 129:227.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/8\" class=\"nounderline abstract_t\">Azor&iacute;n D, Torrelo A, Lassaletta A, et al. Systemic juvenile xanthogranuloma with fatal outcome. Pediatr Dermatol 2009; 26:709.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/9\" class=\"nounderline abstract_t\">Orsey A, Paessler M, Lange BJ, Nichols KE. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50:927.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/10\" class=\"nounderline abstract_t\">Caputo R, Marzano AV, Passoni E, Berti E. Unusual variants of non-Langerhans cell histiocytoses. J Am Acad Dermatol 2007; 57:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/11\" class=\"nounderline abstract_t\">Samara WA, Khoo CT, Say EA, et al. Juvenile Xanthogranuloma Involving the Eye and Ocular Adnexa: Tumor Control, Visual Outcomes, and Globe Salvage in 30 Patients. Ophthalmology 2015; 122:2130.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/12\" class=\"nounderline abstract_t\">Vendal Z, Walton D, Chen T. Glaucoma in juvenile xanthogranuloma. Semin Ophthalmol 2006; 21:191.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/13\" class=\"nounderline abstract_t\">SANDERS TE. Intraocular juvenile xanthogranuloma (nevoxanthogranuloma): a survey of 20 cases. Trans Am Ophthalmol Soc 1960; 58:59.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/14\" class=\"nounderline abstract_t\">Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004; 21:97.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/15\" class=\"nounderline abstract_t\">Ferrari F, Masurel A, Olivier-Faivre L, Vabres P. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol 2014; 150:42.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/16\" class=\"nounderline abstract_t\">Fenot M, Stalder JF, Barbarot S. Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1. J Am Acad Dermatol 2014; 71:389.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/17\" class=\"nounderline abstract_t\">Raygada M, Arthur DC, Wayne AS, et al. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer 2010; 54:173.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/18\" class=\"nounderline abstract_t\">Shin HT, Harris MB, Orlow SJ. Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas. J Pediatr Hematol Oncol 2004; 26:591.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/19\" class=\"nounderline abstract_t\">Benessahraoui M, Aubin F, Paratte F, et al. [Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1]. Arch Pediatr 2003; 10:891.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/20\" class=\"nounderline abstract_t\">Larr&egrave;gue M, Bela&iuml;ch S, Delzant O, Degos R. [Xanthomatoleukemia in young children and Recklinghausen's disease]. Ann Dermatol Syphiligr (Paris) 1972; 99:373.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/21\" class=\"nounderline abstract_t\">Royer P, Blondet C. Xantholeucemie du nourrisson et neurofibromatose de Recklinghausen. Ann Pediatr (Paris) 1958; 24:1504.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/22\" class=\"nounderline abstract_t\">Paulus S, Koronowska S, F&ouml;lster-Holst R. Association Between Juvenile Myelomonocytic Leukemia, Juvenile Xanthogranulomas and Neurofibromatosis Type 1: Case Report and Review of the Literature. Pediatr Dermatol 2017; 34:114.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/23\" class=\"nounderline abstract_t\">Burgdorf WH, Zelger B. JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr Dermatol 2004; 21:174.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/24\" class=\"nounderline abstract_t\">Song M, Kim SH, Jung DS, et al. Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol 2011; 25:259.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/25\" class=\"nounderline abstract_t\">Breier F, Zelger B, Reiter H, et al. Papular xanthoma: a clinicopathological study of 10 cases. J Cutan Pathol 2002; 29:200.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/26\" class=\"nounderline abstract_t\">Chen CG, Chen CL, Liu HN. Primary papular xanthoma of children: a clinicopathologic, immunohistopathologic and ultrastructural study. Am J Dermatopathol 1997; 19:596.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/27\" class=\"nounderline abstract_t\">Fonseca E, Contreras F, Cuevas J. Papular xanthoma in children: report and immunohistochemical study. Pediatr Dermatol 1993; 10:139.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/28\" class=\"nounderline abstract_t\">Caputo R, Gianni E, Imondi D, et al. Papular xanthoma in children. J Am Acad Dermatol 1990; 22:1052.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/29\" class=\"nounderline abstract_t\">Busam KJ, Granter SR, Iversen K, Jungbluth AA. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. Am J Dermatopathol 2000; 22:237.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/30\" class=\"nounderline abstract_t\">Caputo R, Veraldi S, Grimalt R, et al. The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatology 1995; 190:19.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/31\" class=\"nounderline abstract_t\">Park M, Boone B, Devos S. Xanthoma disseminatum: case report and mini-review of the literature. Acta Dermatovenerol Croat 2014; 22:150.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/32\" class=\"nounderline abstract_t\">Gong HZ, Zheng HY, Li J. Xanthoma disseminatum. Lancet 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/33\" class=\"nounderline abstract_t\">Gianotti F, Caputo R. Histiocytic syndromes: a review. J Am Acad Dermatol 1985; 13:383.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/34\" class=\"nounderline abstract_t\">Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51:130.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/35\" class=\"nounderline abstract_t\">Nakasu S, Tsuji A, Fuse I, Hirai H. Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery. J Neurooncol 2007; 84:99.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/36\" class=\"nounderline abstract_t\">De Paula AM, Andr&eacute; N, Fernandez C, et al. Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer 2010; 55:380.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/37\" class=\"nounderline abstract_t\">M&uuml;ller RP, Busse H. [Radiotherapy in juvenile xanthogranuloma of the iris]. Klin Monbl Augenheilkd 1986; 189:15.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/38\" class=\"nounderline abstract_t\">Wang B, Jin H, Zhao Y, Ma J. The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir (Wien) 2016; 158:1289.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/39\" class=\"nounderline abstract_t\">Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009; 52:413.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/40\" class=\"nounderline abstract_t\">Maintz L, Wenzel J, Irnich M, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol 2017; 176:481.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/41\" class=\"nounderline abstract_t\">Bailey KM, Castle VP, Hummel JM, et al. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. J Pediatr Hematol Oncol 2012; 34:480.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-xanthogranuloma-jxg/abstract/42\" class=\"nounderline abstract_t\">Hu WK, Gilliam AC, Wiersma SR, Dahms BB. Fatal congenital systemic juvenile xanthogranuloma with liver failure. Pediatr Dev Pathol 2004; 7:71.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13729 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12028624\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H12028554\" id=\"outline-link-H12028554\">INTRODUCTION</a></li><li><a href=\"#H12028561\" id=\"outline-link-H12028561\">EPIDEMIOLOGY</a></li><li><a href=\"#H12028568\" id=\"outline-link-H12028568\">PATHOGENESIS</a></li><li><a href=\"#H432992506\" id=\"outline-link-H432992506\">PATHOLOGY</a></li><li><a href=\"#H12028575\" id=\"outline-link-H12028575\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H5404120\" id=\"outline-link-H5404120\">Clinical presentation</a></li><li><a href=\"#H5404113\" id=\"outline-link-H5404113\">Clinical course</a></li><li><a href=\"#H12028582\" id=\"outline-link-H12028582\">Ocular JXG</a></li></ul></li><li><a href=\"#H432992837\" id=\"outline-link-H432992837\">ASSOCIATED CONDITIONS</a></li><li><a href=\"#H12028603\" id=\"outline-link-H12028603\">DIAGNOSIS</a></li><li><a href=\"#H5404435\" id=\"outline-link-H5404435\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H12028610\" id=\"outline-link-H12028610\">MANAGEMENT</a><ul><li><a href=\"#H21221319\" id=\"outline-link-H21221319\">Cutaneous JXG</a></li><li><a href=\"#H21221326\" id=\"outline-link-H21221326\">Subcutaneous and soft tissue JXG</a></li><li><a href=\"#H21221333\" id=\"outline-link-H21221333\">Ocular JXG</a></li><li><a href=\"#H21221340\" id=\"outline-link-H21221340\">Symptomatic systemic JXG</a></li></ul></li><li><a href=\"#H12028617\" id=\"outline-link-H12028617\">PROGNOSIS</a></li><li><a href=\"#H12028624\" id=\"outline-link-H12028624\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13729|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/69122\" class=\"graphic graphic_picture\">- Juvenile xanthogranuloma solitary lesion</a></li><li><a href=\"image.htm?imageKey=DERM/81058\" class=\"graphic graphic_picture\">- JXG multiple lesions</a></li><li><a href=\"image.htm?imageKey=DERM/68132\" class=\"graphic graphic_picture\">- JXG leg</a></li><li><a href=\"image.htm?imageKey=DERM/81386\" class=\"graphic graphic_picture\">- JXG single face nodule</a></li><li><a href=\"image.htm?imageKey=DERM/59377\" class=\"graphic graphic_picture\">- JXG single face nodule 2</a></li><li><a href=\"image.htm?imageKey=DERM/68597\" class=\"graphic graphic_picture\">- Juvenile xanthogranuloma multiple scalp</a></li><li><a href=\"image.htm?imageKey=DERM/56332\" class=\"graphic graphic_picture\">- Intraocular juvenile xanthogranuloma</a></li><li><a href=\"image.htm?imageKey=DERM/75895\" class=\"graphic graphic_picture\">- Juvenile xanthogranuloma periocular</a></li><li><a href=\"image.htm?imageKey=DERM/69504\" class=\"graphic graphic_picture\">- Langerhans histiocytosis skin 2</a></li><li><a href=\"image.htm?imageKey=DERM/72187\" class=\"graphic graphic_picture\">- Papular xanthoma</a></li><li><a href=\"image.htm?imageKey=DERM/104995\" class=\"graphic graphic_picture\">- Tuberous xanthomas on knee</a></li><li><a href=\"image.htm?imageKey=DERM/72875\" class=\"graphic graphic_picture\">- Tuberous xanthoma</a></li><li><a href=\"image.htm?imageKey=DERM/104996\" class=\"graphic graphic_picture\">- Tuberous xanthomas on elbow</a></li><li><a href=\"image.htm?imageKey=DERM/80221\" class=\"graphic graphic_picture\">- Mastocytoma solitary</a></li><li><a href=\"image.htm?imageKey=DERM/50284\" class=\"graphic graphic_picture\">- Mastocytoma extremity</a></li><li><a href=\"image.htm?imageKey=DERM/62471\" class=\"graphic graphic_picture\">- Eruptive xanthoma</a></li></ul></li><li><div id=\"DERM/13729|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/59870\" class=\"graphic graphic_table\">- Immunohistochemical differential diagnosis of JXG</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations and diagnosis of chronic myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">Cutaneous xanthomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=langerhans-cell-histiocytosis-eosinophilic-granuloma-of-bone-in-children-and-adolescents\" class=\"medical medical_review\">Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mastocytosis-cutaneous-and-systemic-epidemiology-pathogenesis-and-clinical-manifestations\" class=\"medical medical_review\">Mastocytosis (cutaneous and systemic): Epidemiology, pathogenesis, and clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin\" class=\"medical medical_review\">Overview of benign lesions of the skin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-glaucoma-in-infants-and-children\" class=\"medical medical_review\">Overview of glaucoma in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spitzoid-melanocytic-neoplasms-spitz-nevus-and-atypical-spitz-tumors\" class=\"medical medical_review\">Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)</a></li></ul></div></div>","javascript":null}